The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma
Open accessAbstract
Our group recently demonstrated that autoimmune T cells directed against central nervous system-associated myelin antigens protect neurons from secondary degeneration. We further showed that the synthetic peptide copolymer 1 (Cop-1), known to suppress experimental autoimmune encephalomyelitis, can be safely substituted for the natural myelin antigen in both passive and active immunization for neuroprotection of the injured optic nerve. Here we attempted to determine whether similar immunizations are protective from retinal ganglion cell loss resulting from a direct biochemical insult caused, for example, by glutamate (a major mediator of degeneration in acute and chronic optic nerve insults) and in a rat model of ocular hypertension. Passive immunization with T cells reactive to myelin basic protein or active immunization with myelin oligodendrocyte glycoprotein-derived peptide, although neuroprotective after optic nerve injury, was ineffective against glutamate toxicity in mice and rats. In contrast, the number of surviving retinal ganglion cells per square millimeter in glutamate-injected retinas was significantly larger in mice immunized 10 days previously with Cop-1 emulsified in complete Freund's adjuvant than in mice injected with PBS in the same adjuvant (2,133 ± 270 and 1,329 ± 121, respectively, mean ± SEM;P< 0.02). A similar pattern was observed when mice were immunized on the day of glutamate injection (1,777 ± 101 compared with 1,414 ± 36;P< 0.05), but not when they were immunized 48 h later. These findings suggest that protection from glutamate toxicity requires reinforcement of the immune system by antigens that are different from those associated with myelin. The use of Cop-1 apparently circumvents this antigen specificity barrier. In the rat ocular hypertension model, which simulates glaucoma, immunization with Cop-1 significantly reduced the retinal ganglion cell loss from 27.8% ± 6.8% to 4.3% ± 1.6%, without affecting the intraocular pressure. This study may point the way to a therapy for glaucoma, a neurodegenerative disease of the optic nerve often associated with increased intraocular pressure, as well as for acute and chronic degenerative disorders in which glutamate is a prominent participant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological agents acting at subtypes of metabotropic glutamate receptors
Schoepp, D. D., Jane, D. E., & Monn, J. A. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00092-1 · Cited by 1,060
Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy
Moalem, G., Leibowitz–Amit, R., Yoles, E., Mor, F., Cohen, I. R., & Schwartz, M. (1999) · Nature Medicine · doi:10.1038/4734 · Cited by 889
Self-citationGlutamate excitotoxicity in a model of multiple sclerosis
Pitt, D., Werner, P., & Raine, C. S. (2000) · Nature Medicine · doi:10.1038/71555 · Cited by 744
The Role of Excitotoxicity in Neurodegenerative Disease
Doble, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00042-4 · Cited by 723
Sendtner, M., Holtmann, B., Kolbeck, R., Thoenen, H., & Barde, Y.-A. (1992) · Nature · doi:10.1038/360757a0 · Cited by 707
Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death
Yan, Q., Elliott, J., & Snider, W. D. (1992) · Nature · doi:10.1038/360753a0 · Cited by 661
Elevated Glutamate Levels in the Vitreous Body of Humans and Monkeys With Glaucoma
Dreyer, E. B. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100130295012 · Cited by 659
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide
Teitelbaum, D., Meshorer, A., Hirshfeld, T., Arnon, R., & Sela, M. (1971) · European Journal of Immunology · doi:10.1002/eji.1830010406 · Cited by 433
Neufeld, A. H., Sawada, A., & Becker, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9944 · Cited by 374
Hauben, E., Butovsky, O., Nevo, U., Yoles, E., Moalem, G., Agranov, E., Mor, F., Leibowitz-Amit, R., Pevsner, E., Akselrod, S., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06421.2000 · Cited by 367
Self-citationProtective Autoimmunity Is a Physiological Response to CNS Trauma
Yoles, E., Hauben, E., Palgi, O., Agranov, E., Gothilf, A., Cohen, A., Kuchroo, V., Cohen, I. R., Weiner, H., & Schwartz, M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-11-03740.2001 · Cited by 344
Self-citationInnate and adaptive immune responses can be beneficial for CNS repair
Schwartz, M., Moalem, G., Leibowitz-Amit, R., & Cohen, I. R. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01405-8 · Cited by 341
Self-citationProduction of Neurotrophins by Activated T Cells: Implications for Neuroprotective Autoimmunity
Moalem, G., Gdalyahu, A., Shani, Y., Otten, U., Lazarovici, P., Cohen, I. R., & Schwartz, M. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.2000.0441 · Cited by 338
Self-citationKipnis, J., Yoles, E., Porat, Z., Cohen, A., Mor, F., Sela, M., Cohen, I. R., & Schwartz, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7446 · Cited by 308
Self-citationNeuhaus, O., Farina, C., Yassouridis, A., Wiendl, H., Then Bergh, F., Dose, T., Wekerle, H., & Hohlfeld, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7452 · Cited by 299
Aharoni, R., Teitelbaum, D., Sela, M., & Arnon, R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10821 · Cited by 274
Autoimmune T cells as potential neuroprotective therapy for spinal cord injury
Hauben, E., Nevo, U., Yoles, E., Moalem, G., Agranov, E., Mor, F., Akselrod, S., Neeman, M., Cohen, I., & Schwartz, M. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05140-5 · Cited by 213
Self-citationElevation of Intraocular Glutamate Levels in Rats With Partial Lesion of the Optic Nerve
Yoles, E. (1998) · Archives of Ophthalmology · doi:10.1001/archopht.116.7.906 · Cited by 173
Self-citationAharoni, R., Teitelbaum, D., Sela, M., & Arnon, R. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00166-0 · Cited by 173
Vaccination for Neuroprotection in the Mouse Optic Nerve: Implications for Optic Neuropathies
Fisher, J., Levkovitch-Verbin, H., Schori, H., Yoles, E., Butovsky, O., Kaye, J. F., Ben‐Nun, A., & Schwartz, M. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-01-00136.2001 · Cited by 156
Self-citationTeitelbaum, D., Fridkis‐Hareli, M., Arnon, R., & Sela, M. (1996) · Journal of Neuroimmunology · doi:10.1016/0165-5728(95)00180-8 · Cited by 153
Moalem‐Taylor, G., Monsonego, A., Shani, Y., Cohen, I. R., & Schwartz, M. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.10.1207 · Cited by 152
Self-citationIs Neuroprotection a Viable Therapy for Glaucoma?
Weinreb, R. N. (1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.11.1540 · Cited by 114
Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1.
Teitelbaum, D., Aharoni, R., Arnon, R., & Sela, M. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.24.9724 · Cited by 113
Promiscuous Binding of Synthetic Copolymer 1 to Purified HLA-DR Molecules
Fridkis‐Hareli, M., & Strominger, J. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4386 · Cited by 111
Grünblatt, E., Mandel, S. A., & Youdim, M. B. H. (2000) · Journal of Neurology · doi:10.1007/pl00022909 · Cited by 109
Ben‐Nun, A., Mendel, I., Bakimer, R., Fridkis‐Hareli, M., Teitelbaum, D., Arnon, R., Sela, M., & de Rosbo, N. K. (1996) · Journal of Neurology · doi:10.1007/bf00873697 · Cited by 105
Webb, C., Teitelbaum, D., Arnon, R., & Sela, M. (1973) · European Journal of Immunology · doi:10.1002/eji.1830030506 · Cited by 103
Hirschberg, D. L., Moalem‐Taylor, G., He, J., Mor, F., Cohen, I. R., & Schwartz, M. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00118-0 · Cited by 91
Self-citationAharoni, R., Teitelbaum, D., & Arnon, R. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230105 · Cited by 86
The potential of neuroprotection in glaucoma treatment
Osborne, N. N., Chidlow, G., Nash, M. S., & Wood, J. P. M. (1999) · Current Opinion in Ophthalmology · doi:10.1097/00055735-199904000-00002 · Cited by 83
MK801—a neuroprotectant in rat hypertensive eyes
Chaudhary, P., Ahmed, F. A. K. M., & Sharma, S. C. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00212-1 · Cited by 81
Intraocular pressure and visual field progression in open-angle glaucoma
Kass, M. A., & Gordon, M. O. (2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00658-9 · Cited by 39
Neuroprotection: a new treatment modality for glaucoma?
Schwartz, M., & Yoles, E. (2000) · Current Opinion in Ophthalmology · doi:10.1097/00055735-200004000-00007 · Cited by 39
Self-citationBräuner‐Osborne, H., Hermit, M. B., Nielsen, B., Krogsgaard‐Larsen, P., & Johansen, T. N. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00625-7 · Cited by 18
Cited by
Weinreb, R. N., & Khaw, P. T. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16257-0 · Cited by 2,222
The retina as a window to the brain—from eye research to CNS disorders
London, A., Benhar, I., & Schwartz, M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.227 · Cited by 1,403
Self-citationKipnis, J., Cohen, H., Cardon, M., Ziv, Y., & Schwartz, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402268101 · Cited by 510
Self-citationMicroglial phenotype: is the commitment reversible?
Schwartz, M., Butovsky, O., Brück, W., & Hanisch, U.-K. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2005.12.005 · Cited by 434
Self-citationButovsky, O., Talpalar, A. E., Ben-Yaakov, K., & Schwartz, M. (2005) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.03.005 · Cited by 365
Self-citation
Metadata
- Authors
- Schori, H., Kipnis, J., Yoles, E., WoldeMussie, E., Ruiz, G., Wheeler, L. A., & Schwartz, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2001-03-06
- Volume
- 98
- Issue
- 6
- Pages
- 3398-3403
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2117976722
- Cited by
- 286
- References
- 35
- FWCI
- 27.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.